Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

ω-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity.

Bi X, Li F, Liu S, Jin Y, Zhang X, Yang T, Dai Y, Li X, Zhao AZ.

J Clin Invest. 2017 May 1;127(5):1757-1771. doi: 10.1172/JCI87388. Epub 2017 Apr 4.

2.

T-cell Metabolism as a Target to Control Autoreactive T Cells in β-Cell Autoimmunity.

Bordignon C, Canu A, Dyczko A, Leone S, Monti P.

Curr Diab Rep. 2017 May;17(5):24. doi: 10.1007/s11892-017-0848-5. Review.

3.

Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.

Malmegrim KC, de Azevedo JT, Arruda LC, Abreu JR, Couri CE, de Oliveira GL, Palma PV, Scortegagna GT, Stracieri AB, Moraes DA, Dias JB, Pieroni F, Cunha R, Guilherme L, Santos NM, Foss MC, Covas DT, Burt RK, Simões BP, Voltarelli JC, Roep BO, Oliveira MC.

Front Immunol. 2017 Feb 22;8:167. doi: 10.3389/fimmu.2017.00167. eCollection 2017.

4.

Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Kean LS, Turka LA, Blazar BR.

Immunol Rev. 2017 Mar;276(1):192-212. doi: 10.1111/imr.12523. Review.

PMID:
28258702
5.

Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

Visperas A, Vignali DA.

J Immunol. 2016 Nov 15;197(10):3762-3770. Review.

PMID:
27815439
6.

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.

Todd JA, Evangelou M, Cutler AJ, Pekalski ML, Walker NM, Stevens HE, Porter L, Smyth DJ, Rainbow DB, Ferreira RC, Esposito L, Hunter KM, Loudon K, Irons K, Yang JH, Bell CJ, Schuilenburg H, Heywood J, Challis B, Neupane S, Clarke P, Coleman G, Dawson S, Goymer D, Anselmiova K, Kennet J, Brown J, Caddy SL, Lu J, Greatorex J, Goodfellow I, Wallace C, Tree TI, Evans M, Mander AP, Bond S, Wicker LS, Waldron-Lynch F.

PLoS Med. 2016 Oct 11;13(10):e1002139. doi: 10.1371/journal.pmed.1002139. eCollection 2016 Oct.

7.

Endoplasmic reticulum stress in beta cells and autoimmune diabetes.

Clark AL, Urano F.

Curr Opin Immunol. 2016 Dec;43:60-66. doi: 10.1016/j.coi.2016.09.006. Epub 2016 Oct 5. Review.

PMID:
27718448
8.

Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway.

Adams AB, Ford ML, Larsen CP.

J Immunol. 2016 Sep 15;197(6):2045-50. doi: 10.4049/jimmunol.1601135.

PMID:
27591335
9.

Biomarkers of β-Cell Stress and Death in Type 1 Diabetes.

Mirmira RG, Sims EK, Syed F, Evans-Molina C.

Curr Diab Rep. 2016 Oct;16(10):95. doi: 10.1007/s11892-016-0783-x. Review.

PMID:
27541297
10.

ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.

Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, Freedman MS, Arnold DL, Sayre PH, Smilek DE; ACCLAIM Study Group.

Mult Scler. 2017 Apr;23(5):686-695. doi: 10.1177/1352458516662727. Epub 2016 Aug 5.

PMID:
27481207
11.

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.

Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2016 Oct;39(10):1664-70. doi: 10.2337/dc16-0360. Epub 2016 Jul 15.

PMID:
27422577
12.

Staging the progression to type 1 diabetes with prediagnostic markers.

Sosenko JM.

Curr Opin Endocrinol Diabetes Obes. 2016 Aug;23(4):297-305. doi: 10.1097/MED.0000000000000267.

PMID:
27362539
13.

Nucleic acid biomarkers of β cell stress and death in type 1 diabetes.

Syed F, Evans-Molina C.

Curr Opin Endocrinol Diabetes Obes. 2016 Aug;23(4):312-7. doi: 10.1097/MED.0000000000000261.

PMID:
27254268
14.

Progress and challenges for treating Type 1 diabetes.

Garyu JW, Meffre E, Cotsapas C, Herold KC.

J Autoimmun. 2016 Jul;71:1-9. doi: 10.1016/j.jaut.2016.04.004. Epub 2016 May 17. Review.

PMID:
27210268
15.

Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.

Pinckney A, Rigby MR, Keyes-Elstein L, Soppe CL, Nepom GT, Ehlers MR.

Clin Ther. 2016 Jun;38(6):1327-39. doi: 10.1016/j.clinthera.2016.04.032. Epub 2016 May 18.

16.

CD28 Costimulation: From Mechanism to Therapy.

Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA.

Immunity. 2016 May 17;44(5):973-88. doi: 10.1016/j.immuni.2016.04.020. Review.

17.

Strategies for clinical trials in type 1 diabetes.

Ehlers MR.

J Autoimmun. 2016 Jul;71:88-96. doi: 10.1016/j.jaut.2016.03.008. Epub 2016 Apr 5. Review.

PMID:
27068279
18.

The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes.

Tai N, Wong FS, Wen L.

J Autoimmun. 2016 Jul;71:26-34. doi: 10.1016/j.jaut.2016.03.006. Epub 2016 Mar 24. Review.

PMID:
27021275
19.

Life and death of β cells in Type 1 diabetes: A comprehensive review.

Wilcox NS, Rui J, Hebrok M, Herold KC.

J Autoimmun. 2016 Jul;71:51-8. doi: 10.1016/j.jaut.2016.02.001. Epub 2016 Mar 24. Review.

PMID:
27017348
20.

A model-based approach to sample size estimation in recent onset type 1 diabetes.

Bundy BN, Krischer JP; Type 1 Diabetes TrialNet Study Group.

Diabetes Metab Res Rev. 2016 Nov;32(8):827-834. doi: 10.1002/dmrr.2800. Epub 2016 Apr 21.

PMID:
26991448

Supplemental Content

Support Center